Articles related to CARDIOVASCULAR DISEASE (CVD)

“Those with very extreme Lp(a) levels have an almost 10% higher absolute risk of developing CVD across 30-years of follow-up.” – Ask T. Nordestgaard, lead author

Women had a 45% higher relative risk for death, heart attack, or heart failure hospitalization when taking beta-blockers compared to non-beta-blocker groups, with the risk confined to those with preserved LVEF and higher doses.

Patients, with or without anemia, should be screened for elevated homocysteine or B12 deficiency because that may be one of the reversible factors in their cognitive decline.

More than 99% of people who experienced a heart attack, heart failure, or stroke had at least one of four major cardiovascular risk factors above ideal healthy levels beforehand.

A balanced combination of coffee and tea, in a roughly 2:3 ratio, was linked to the lowest risk of death from all causes and several specific diseases.

In the STEER study, patients using Wegovy® had greater cardiovascular improvements compared to tirzepatide, indicating that the same CV benefit cannot be generalized across other molecules in the GLP-1 or GIP/GLP-1 classes and may come specifically from the semaglutide molecule.